Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs Erlotinib in Advanced Squamous NSCLC (LUX-Lung 8)
NCT01523587Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of afatinib in lung squamous cell carcinoma (LSCC), sponsored by Boehringer Ingelheim. Started Mar 2012; status: completed.
02
Drugs
afatinib
03
Conditions
lung squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT01523587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01523587.